The newly established institute is equipped with advanced infrastructure designed to integrate multiple specialties under one roof
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
Subscribe To Our Newsletter & Stay Updated
